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Abstract
Background: Although levels of iron are known to be increased in the brains of patients with Parkinson disease (PD),
epidemiological evidence on a possible effect of iron blood levels on PD risk is inconclusive, with effects reported in
opposite directions. Epidemiological studies suffer from problems of confounding and reverse causation, and mendelian
randomization (MR) represents an alternative approach to provide unconfounded estimates of the effects of biomarkers on
disease. We performed a MR study where genes known to modify iron levels were used as instruments to estimate the
effect of iron on PD risk, based on estimates of the genetic effects on both iron and PD obtained from the largest sample
meta-analyzed to date.
Methods and Findings: We used as instrumental variables three genetic variants influencing iron levels, HFE rs1800562, HFE
rs1799945, and TMPRSS6 rs855791. Estimates of their effect on serum iron were based on a recent genome-wide meta-
analysis of 21,567 individuals, while estimates of their effect on PD risk were obtained through meta-analysis of genome-
wide and candidate gene studies with 20,809 PD cases and 88,892 controls. Separate MR estimates of the effect of iron on
PD were obtained for each variant and pooled by meta-analysis. We investigated heterogeneity across the three estimates
as an indication of possible pleiotropy and found no evidence of it. The combined MR estimate showed a statistically
significant protective effect of iron, with a relative risk reduction for PD of 3% (95% CI 1%–6%; p= 0.001) per 10 mg/dl
increase in serum iron.
Conclusions: Our study suggests that increased iron levels are causally associated with a decreased risk of developing PD.
Further studies are needed to understand the pathophysiological mechanism of action of serum iron on PD risk before
recommendations can be made.
Please see later in the article for the Editors’ Summary.
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Introduction
Iron is involved in fundamental biochemical activities, such as
oxygen delivery, mitochondrial respiration, and DNA synthesis in
almost all cell types. In the brain, iron is a cofactor for a large
number of enzymes, including key enzymes of neurotransmitter
biosynthesis, such as the tyrosine hydroxylase, which represents
the rate-limiting enzyme of dopamine synthesis [1]. However, iron
is also potentially toxic as an excess of free iron contributes to the
generation of reactive oxygen species and can favor oxidative
tissue damage [1]. In the brains of patients with Parkinson disease
(PD), increased levels of iron in the substantia nigra (SN) and the
lateral globus pallidus have been observed, and yet the mecha-
nisms responsible for this phenomenon are not completely
understood [2,3]. PD is characterized by the rather selective loss
of dopaminergic neurons [4] and the presence of a-synuclein-
enriched Lewy body inclusions in the SN [5], and several studies
have demonstrated that free iron in the SN can enhance the
aggregation of a-synuclein and may thus promote the formation of
Lewy bodies [1].
Limited epidemiological evidence on the relationship between
peripheral blood levels of iron and PD risk is available. A recent
meta-analysis of ten studies, with a total of 520 PD cases and 711
controls, showed a trend for lower serum iron levels in PD patients
compared with controls, although the difference in iron levels was
not statistically significant (standardized mean difference: 20.45;
95% CI 20.98 to 0.08; p=0.09) [6]. However, the very large
degree of heterogeneity observed across studies (I2: 93%;
p,0.0001) makes it difficult to interpret these findings.
A major limitation of observational studies is the difficulty in
distinguishing between causal and spurious associations due to
problems of confounding and reverse causation. Mendelian
randomization (MR) is an approach based on the use of genes
as instrumental variables, which has been proposed to assess
causality and provide estimates of the effect of modifiable
intermediate phenotypes on disease unaffected by classical
confounding or reverse causation, whenever randomized clinical
trials are not feasible [7]. Genes are randomly allocated at
conception, so that genetic effects on the intermediate phenotype
cannot be affected by classical confounding, such as lifestyle
factors, or reverse causation, as in the situation where the
phenotype level is influenced by the presence of the disease [8].
For this reason, demonstration that a genetic polymorphism
known to modify the phenotype level also modifies the disease risk
represents indirect evidence of a causal association between
phenotype and disease.
The MR estimate of the effect of the intermediate phenotype on
the disease is derived from the estimates of the associations of the
polymorphism with both intermediate phenotype and disease.
MR, as any other instrumental variable approach, has low
statistical power and therefore requires very large sample sizes [9].
The recent availability of large collections of genome-wide data on
intermediate phenotypes, such as blood biomarkers, and disease
traits within international consortia represents a great opportunity
to exploit the potentials of this approach, and indeed MR studies
have become increasingly popular over the last few years.
The validity of the MR approach relies on the crucial
assumption that the polymorphism acts on the disease only
through the intermediate phenotype of interest and not through
others (assumption of no pleiotropy) [8]. Evaluating the possibility
of pleiotropic effects of the polymorphism is therefore fundamental
when using MR, and yet pleiotropy can only be excluded with
confidence if the function of the gene and its polymorphisms is
completely known, which is rarely the case. This problem can be
addressed by using multiple instruments (polymorphisms in
multiple genes influencing the same intermediate phenotype),
since in the absence of pleiotropy, similar MR estimates should be
obtained regardless of the instrument used, so that differences
across MR estimates beyond what can be expected by chance can
indicate the presence of pleiotropy [10].
In this study, we provide evidence on the presence, direction,
and magnitude of a causal effect of serum iron levels on PD risk by
performing a MR study, based on iron data in 21,567 individuals
from the general population and PD data from 20,809 PD cases
and 88,892 controls. We used three polymorphisms as instruments
in order both to increase statistical power by combining their MR
estimates and to investigate the possible presence of pleiotropy.
Methods
Mendelian Randomization Approach
The selection of the genes modifying iron levels to be used as
instruments in our MR study was based on published results
showing that polymorphisms in the hemochromatosis (HFE,
ENSG00000010704) gene and the transmembrane protease 6
(TMPRSS6, ENSG00000187045) gene have the strongest effects
on serum iron in the general population of European ancestry
[11]. The choice of the polymorphisms within these two genes was
based on the findings of a recent large meta-analysis of genome-
wide association (GWA) studies on iron levels in the general
population (unpublished data). We selected the polymorphisms
with the strongest statistical evidence, two for the HFE gene,
rs1800562 (C282Y) and rs1799945 (H63D), which are not in
linkage disequilibrium (HapMap CEU r2,0.01) and therefore
represent independent signals of association, and one for the
TMPRSS6 gene, rs855791 (V736A) (Figure 1).
Our MR approach was based on the use of aggregate results for
both the gene–iron and gene–PD associations: for each polymor-
phism, we performed a meta-analysis of studies investigating its
effect on iron levels and a meta-analysis of studies investigating its
effect on PD risk, with no studies contributing to both meta-
analyses (see next sections). Three separate MR estimates of the
effect of iron on PD were obtained for the three polymorphisms,
and they were subsequently pooled by meta-analysis to provide a
single MR estimate. Heterogeneity between the three MR
estimates was investigated to detect the possible presence of
pleiotropy.
Data on Gene Associations with Iron
Estimates of the effect sizes of the three polymorphisms in HFE
and TMPRSS6 on total serum iron levels was based on the findings
of a recent GWA meta-analysis on iron parameters performed by
the Genetics of Iron Status (GIS) Consortium (Table 1) (unpub-
lished data). The GIS meta-analysis includes ten cohorts from
eight participating research groups. The individual datasets
included in the meta-analysis are described in Table S1.
Data on Gene Associations with PD Risk
To estimate the association of the three polymorphisms with PD
risk, we performed a meta-analysis of both candidate gene and
GWA studies (Table 1).
Candidate gene studies were identified using PDGene (http://
www.pdgene.org), a database providing a regularly updated
synopsis of genetic association studies performed in PD [12].
These studies provided data for the two polymorphisms in HFE,
rs1800562 and rs1799945. A total of nine studies were included in
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our analysis for both rs1800562 [13–20] and rs1799945 [13–
17,19–21] (Tables 1 and S2).
Three large international GWA studies recently published, the
PD GWAS Consortium [22], the 23andMe study [23], and the
International Parkinson’s Disease Genomics Consortium (IPDGC)
[24,25], provided data for all three polymorphisms (Table 1). The
PD GWAS Consortium includes data from five studies: PRO-
GENI/GenePD [26], NIA Phase I [27], NIA Phase II [28],
HIHG [29], and NGRC [30]. The 23andMe data come from a
slightly expanded version of the cohort used in [23], including
more than 4,000 PD cases and 60,000 controls. From the IPDGC,
four GWA studies were included in our analysis, together with five
studies genotyped with a custom genotyping array (Immunochip
Illumina iSelect array); the USA-NIA and the USA-dbGAP
studies were not included because of overlap with the PD GWAS
dataset, and the Icelandic study was not available for analysis.
Figure 1. Graphical representation of the MR approach, with all estimates used to derive the final MR estimate. *Reported is the allele
that increases iron levels, together with its frequency (AF). **This corresponds approximately to an OR per unit mg/dl increase in iron of 0.997 (95%CI
0.994–0.999), that is 0.3% (0.1%–0.6%) relative reduction in PD risk per 1 mg/dl increase in iron.
doi:10.1371/journal.pmed.1001462.g001
Table 1. Characteristics of the studies included for the gene–iron and gene–PD associations.
Data Source n studies Type of Study Maximum Sample Size
Gene–iron association
GIS Consortiuma 10 GWA 21,567
Gene–PD association
PDGene database [13–21] 9 Candidate gene studies (HFE rs1800562
and HFE rs1799945)
2,384 cases; 6,908 controls
PD GWAS Consortium [22] 5 GWA 4,238 cases; 4,239 controls
23andMe [23]b 1 GWA 4,127 cases; 62,037 controls
IPDGC [24,25]c 4 GWA 4,258 cases; 10,152 controls
IPDGC [24,25] 5 Immunochip genotyping 5,802 cases; 5,556 controls
Details on individual datasets are reported in Text S1 and in Tables S1 and S2.
aUnpublished data. The original sample size was 22,444, but genotype and phenotype data were available only for 21,567.
b23andMe: slightly expanded version of the cohort used in [23].
cIPDGC: USA-NIA and USA-dbGAP studies were not included in our analysis due to overlap with PD GWAS Consortium; the Icelandic dataset was not available for
analysis.
doi:10.1371/journal.pmed.1001462.t001
Serum Iron Levels and Parkinson Disease
PLOS Medicine | www.plosmedicine.org 4 June 2013 | Volume 10 | Issue 6 | e1001462
A detailed description of the individual datasets is reported in
Text S1 and in Table S2.
Statistical Analyses
GIS meta-analysis results for the gene–iron association were
expressed in terms of Z-score, that is the number of standard
deviations (SDs) above the mean iron level associated with each
copy of the allele.
Study results for the candidate gene studies investigating the
gene–PD risk association were obtained either from the PDGene
website or directly from the original papers [18–20]. For two
studies, estimates of the associations of interest were not provided,
but they could be calculated from the data reported, by
performing a per-genotype analysis based on an additive genetic
model [19], or a per-allele analysis when genotype data were not
available [20]. For the gene–PD meta-analysis, estimates of the
(log) odds ratio (OR) were combined across studies using an
inverse-variance-weighted fixed-effect model and assuming an
additive genetic model, consistently with the gene–iron meta-
analysis.
As for the instrumental variable analysis, an MR estimate of the
effect of iron on PD risk was obtained for each of the three
instruments separately, and the three estimates were combined
using an inverse-variance-weighted fixed-effect meta-analysis. We
evaluated the presence and magnitude of heterogeneity across the
three instruments with the I2 statistics, a measure defined as the
percentage of total variation in study estimates explained by
heterogeneity rather than sampling error [31]. MR estimates were
derived using the Wald-type estimator [32]:
log ORPD=iron~log ORPD=allele=betairon=allele
where log ORPD/iron is the (log) increase of PD risk by SD unit
increase in iron (MR estimate), log ORPD/allele is the (log) increase
in PD risk per allele (gene–PD association), and betairon/allele is the
number of SDs above the mean iron level per allele (gene–iron
association). The standard error of the MR estimate was derived
using the Delta method [33,34]. The MR estimate is presented in
terms of OR, by exponentiating the log ORPD/iron.
We evaluated the strength of each instrument using the F
statistics, which is a function of the magnitude and precision of the
genetic effect on the biomarker (iron):
F~R2 n{2ð Þ= 1{R2 
where R2 is the variance of iron blood levels explained by the
genetic variant and n is the sample size for the gene–iron
association. We also evaluated the overall F statistics for the three
combined instruments assuming that their effects were indepen-
dent, as are expected to be given that the three gene variants are
not in linkage disequilibrium.
A sensitivity analysis was performed to investigate the possible
impact on our findings of population stratification in any of the
studies included in the gene–iron or gene–PD analyses, by
excluding studies which had not adjusted for population stratifi-
cation.
All analyses were performed using Stata 10 (StataCorp LP).
Results
Gene Association with Iron
The GIS meta-analysis for iron levels included 21,567
individuals from Europe and Australia (Table S1). The effect on
iron levels, expressed as number of SDs from the mean, was 0.37
(95% CI 0.33–0.41; p = 4.0610277) for each copy of the A allele of
HFE rs1800562, 0.19 (95% CI 0.17–0.21; p = 1.7610242) for the
G allele of HFE rs1799945, and 0.19 (95% CI 0.17–0.21;
p = 4.3610277) for the G allele of TMPRSS6 rs855791 (Figure 1;
Table S3). With a SD for serum iron levels of 37.6 mg/dl, these
figures correspond to an increase in iron per allele of approxi-
mately 13.9, 7.1. and 7.1 mg/dl, respectively. HFE rs1800562,
HFE rs1799945, and TMPRSS6 rs855791 explained 1.7%, 0.9%,
and 1.7% of iron total variance, respectively (Table S3).
The F statistics was very high for all genetic variants, as can be
expected given the sample size of more than 21,000 individuals
[35]: 382, 199, and 379 for HFE rs1800562, HFE rs1799945, and
TMPRSS6 rs855791, respectively. The F statistics for all combined
instruments was 987.
Gene Association with PD Risk
All datasets available for the analysis of the effects of the three
genetic polymorphisms on PD risk (Table S2) were checked for
the presence of overlapping studies, and duplicates were
removed. The meta-analysis, which included a total of 20,809
PD cases and 88,892 controls from Europe and North America
(Table S2), revealed a significant association for TMPRSS6
rs855791 with PD risk, with an OR of 0.97 (95% CI 0.94–0.99;
p = 0.034) per copy of the G allele. As shown in the Forest plot of
the meta-analysis for this polymorphism (Figure S3), there was no
statistical evidence of heterogeneity across studies, with a
heterogeneity test p-value of 0.86 and an I2 of 0% (95% CI
0%–85%). In particular, although the 23andMe study was based
on self-reported disease status and therefore differed from the
rest, its results were consistent with those of the other PD studies.
The association with PD risk for the two polymorphisms in HFE
was not statistically significant, with an OR of 0.97 (95% CI
0.92–1.02; p = 0.281) for the A allele of rs1800562 and 0.99 (95%
CI 0.96–1.03; p = 0.715) for the G allele of rs1799945 (Figures 1,
S1, and S2; Table S4). This might be explained by the much
lower statistical power for the two HFE variants compared with
the TMPRSS6 variant due to their lower minor allele frequency
(1,000 Genomes project: 0.02 and 0.08 versus 0.40), as suggested
by their wide confidence intervals.
Mendelian Randomization Estimate of Iron Association
with PD Risk
The meta-analysis of the three MR estimates resulted in a
statistically significant combined estimate of 0.88 (95% CI 0.82–
0.95; p = 0.001), representing the OR for PD per SD unit
increase in iron (Figure 1). Again, with a SD for iron levels of
37.6 mg/dl, this corresponds approximately to an OR of 0.997
(95% CI 0.994–0.999) per 1 mg/dl increase in iron, that is a
0.3% (95% CI 0.1%–0.6%) relative risk reduction. The Forest
plot in Figure 2 shows how the meta-analysis result was driven
by the TMPRSS6 rs855791 variant, and that there was no
statistical evidence of heterogeneity across instruments (p = 0.54;
I2: 0%, 95% CI 0%–90%), suggesting that the assumption of no
pleiotropy might hold.
The sensitivity analysis investigating the impact of population
stratification excluded the nine studies from PDGene, which had
not reported any adjustment for population stratification, while
there were no exclusions from the GIS consortium on iron since all
studies had adjusted for population stratification (Table S2). The
result of the sensitivity analysis was similar to that of the main
analysis, with a combined MR estimate of 0.91 (95% CI 0.83–
0.99; p = 0.032) (Figure S4).
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Discussion
Our study shows a protective effect of serum iron levels on PD,
with a 3% (95% CI 1%–6%; p = 0.001) relative reduction in PD
risk per 10 mg/dl increase in iron. If we hypothesise increasing
serum iron levels of one SD unit (38 mg/dl in our study) in a
population of Caucasians older than 60, where PD risk is around
1% [36], a corresponding relative risk reduction of 12% would
translate to a decrease in PD cases from 100/10,000 to 88/10,000.
Since genotype influences on serum iron levels represent
differences that generally persist throughout adult life, the estimate
of our MR study reflects an effect of iron over the course of a
lifetime. These findings are important since evidence on the
association between serum iron levels and PD risk collected so far
has been controversial. Although iron is generally thought of as a
risk factor for PD, in line with the well-known phenomenon of iron
accumulation in the brain of PD patients [2,3], epidemiological
studies have shown effects of iron in opposite directions. A recent
meta-analysis of epidemiological studies suggests a possible
protective role of serum iron levels on PD risk, but its findings
are difficult to interpret owing to the very large degree of
heterogeneity across studies [6]. Epidemiological studies suffer
from confounding and reverse causation, which are intrinsic to
their observational nature, so that they can hardly provide
conclusive evidence on the causality of an observed association.
Tobacco smoking and coffee drinking, which have been suggested
as protective factors for PD [37,38], represent two potential
confounders for the association between iron and PD, since both
might have an effect on iron levels. Nicotine might decrease the
availability of free reactive iron [39], and coffee is known to inhibit
the intestinal absorption of iron [40,41]. Reverse causation could
also produce spurious associations in epidemiological studies if the
phenotype level can be influenced by the presence of the disease.
An example is that of monoamine oxidase (MAO) inhibitors used
to treat PD. MAO inhibitors may have iron-chelating effects and
thus reduce iron blood levels, which could lead to spurious
epidemiological evidence of a difference in iron levels between PD
cases and controls [42]. Although causality is usually assessed by
use of randomized clinical trials, the MR approach represents a
valuable alternative whenever these are not feasible [7]. It is based
on the concept that genetic variation modifying the concentration
of a biomarker should also affect the disease risk if (and only if) the
biomarker is directly and causally involved in the disease
pathogenesis. Being genes randomly allocated at conception, their
effects on biomarkers are unaffected by classical confounding
factors and reverse causation [8].
The protective effect of higher serum iron levels on PD risk
found in our study may seem somewhat counterintuitive at first
sight. However, there are several reports in the literature in line
with our findings. A recent study showed a negative correlation
between SN echogenicity, a marker for increased SN iron content
[43], and serum iron levels in PD patients [44]. A case-control
study suggested an increased risk of PD in men who reported
multiple recent blood donations and thus experienced depleted
systemic iron stores [45], and another study showed an association
of anemia experienced early in life with increased PD risk, with the
authors hypothesizing that anemia could be a surrogate marker for
iron deficiency [46]. Finally, in dietary iron-restricted mice
Figure 2. Forest plot of the MR estimates from the three instruments. The size of the squares is proportional to the precision of the MR
estimates for each polymorphism, with the horizontal lines indicating their 95% confidence intervals. The combined MR estimate is represented by
the centre of the diamond, with the lateral tips indicating its 95% confidence interval. The solid vertical line is the line of no effect.
doi:10.1371/journal.pmed.1001462.g002
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impaired motor behavior and a marked decrease of striatal
dopamine levels was observed, which was explained with the fact
that iron is essential for the activity of tyrosine hydroxylase, the
rate-limiting enzyme in the dopamine synthesis [47]. Consistent
with these findings, a recent study performed in Japan found an
association between higher iron intake and reduced PD risk [48].
The underlying mechanisms of the protective effect of iron on
PD risk observed in our study remains unclear, as does the
mechanism that regulates the relationship between serum and
brain iron levels. Low peripheral iron levels may reduce the
functioning of neuronal enzymes or receptors, since iron is a
crucial cofactor of tyrosine hydroxylase [49], plays a role in the
synthesis of monoamine neurotransmitters, and is involved in
dopaminergic neurodevelopment [50]. Furthermore, low iron
levels may decrease neuronal iron storage in the form of ferritin
[51], which was found to be inappropriately low in SN neurons in
PD [1]. A reduction in ferritin could decrease neuronal iron
utilization by decreasing the pool of iron available for neuronal
enzymes [47], thus leading to the accumulation of free iron in SN
[1]. Similar large-scale MR studies investigating other markers of
iron metabolism, such as ferritin and transferrin, could contribute
to our understanding of the role of peripheral iron homeostasis in
the pathophysiology of PD.
To our knowledge, this is the first MR study aimed at estimating
the magnitude of the effect of serum iron levels on PD risk.
Previous case-control studies have tried to assess causality and
direction of the association by investigating the effect on PD risk of
genes involved in iron metabolism and homeostasis, although their
findings are somewhat inconsistent with only some supporting the
hypothesis of a causal association. Among the many genes
evaluated, which include FTL, FTH1, TF, TFRC, IREB2, LTF,
CP, FXN, HFE [52], HPX, HAMP, HFE2 [53], and FTMT [54],
only the G258S polymorphism in the TF gene showed a
statistically significant association with PD [17], although the
finding was not replicated in a subsequent study [55], and a
haplotype in the SLC11A2 gene was found to occur more
frequently in PD [56]. However, all these previous studies were
relatively small and therefore underpowered to detect modest
genetic effects on PD risk. Our MR study used three polymor-
phisms in the HFE and TMPRSS6 genes as instruments. Evidence
on their association with PD risk was obtained through meta-
analysis of several candidate gene studies and three large GWA
studies, including a total of more than 20,000 patients and 88,000
controls, which represents the largest PD case-control sample with
genetic data meta-analyzed to date. Similarly, estimates of the
effect of the three polymorphisms on serum iron levels were based
on results from a recent GWA meta-analysis including more than
21,000 individuals. Unlike similar MR investigations that have
combined multiple instruments into a single allele score using
individual data analyses from all contributing studies, our analyses
required only aggregate results for the effect of each genetic
variant on both biomarker and disease. This may have practical
importance, since it allows inclusion of results from ongoing
genetic consortia without requiring further analyses, as well as
inclusion of previous findings from published reports. However,
methodological work will be needed to assess the relative benefits
of the two approaches under different scenarios.
The crucial aspect of a MR study, and more generally of any
study based on an instrumental variable approach, is the choice of
the gene (instrument) that needs to have a strong effect on the
intermediate phenotype of interest. We used three polymorphisms
as instrumental variables, since the use of multiple instruments
influencing the intermediate phenotype of interest can increase the
statistical power of the MR analysis [10]. The instrument strength
was high for all of them, as shown by their very large F-statistic
values. Two of them, rs1800562 (C282Y) and rs1799945 (H63D),
are non-synonymous polymorphisms in HFE, a gene with well
known effects in the modulation of iron blood levels [57]. The
third non-synonymous polymorphism, rs855791 (V736A), is
located in TMPRSS6, a gene whose role in iron regulation was
demonstrated more recently [58]. The two variants in the HFE
gene are responsible for most cases of hereditary hemochromatosis
[59,60], and they are associated with iron overload when present
in the homozygous (C282Y/C282Y) or compound heterozygous
(C282Y/H63D) state. The C282Y variant prevents the altered HFE
protein from reaching the cell surface and interacting with the
transferrin receptor (TfR) [61,62]. As a result, iron regulation is
disrupted. The exact functional effect of the H63D variant is as yet
unclear, but some evidence suggests that it may alter an
intramolecular salt bridge, possibly affecting the interaction of
the HFE protein with the TfR [63]. The TMPRSS6 V736A variant
was found associated with iron-deficiency anemia [64]. Further-
more, the A allele has been shown to inhibit hepcidin more
efficiently than the V allele in in vitro experiments, and to affect
hepcidin levels in healthy individuals [65]. Interestingly, TMPRSS6
rs855791 was by far the most influential and was the one driving
the result of the meta-analysis of MR estimates from the three
instruments. The wide confidence intervals of the MR estimates
for HFE rs1800562 and rs1799945 suggest that the power of their
MR analysis was very limited due to their low allele frequency.
This illustrates the importance of balancing the strength of the
effect on the intermediate phenotype with allele frequency and
statistical power when choosing the instruments for a MR study.
A potential source of bias specific to MR studies is pleiotropy,
whereby the HFE or TMPRSS6 genotypes could influence PD risk
through another mechanism that is independent of their effect on
serum iron levels. Although we cannot completely exclude pleiotropic
effects of the three polymorphisms used in our study because of
incomplete knowledge of the underlying biology, we can indirectly
investigate the presence of such effects through the simultaneous use
of the three polymorphisms as multiple instruments. In aMR study, if
all instruments are valid, their MR estimates should differ only as a
result of sampling error [10], so that there should be no heterogeneity
in the meta-analysis of MR estimates. In our meta-analysis of MR
estimates there was no evidence of heterogeneity, although the
statistical power to detect heterogeneity is limited when only three
estimates are included in the meta-analysis [66]. As more evidence on
genes influencing iron blood levels becomes available, MR studies
investigating the effects of iron on the risk of PD and other diseases
will be able to include many more genetic variants as instruments.
This will ensure that pleiotropy can be ruled out with greater
confidence. Selection of genes to be used as instruments requires
careful consideration, since inclusion of variants with small genetic
effects on the biomarker may introduce a ‘‘weak instrumental
variable’’ bias [35]. Another potential issue in MR investigations is
developmental canalization, the ability to produce the same
phenotype regardless of genetic (or environmental) variation. If a
genetic polymorphism is expressed during fetal development,
compensatory processes may influence development in a way that
can protect against the effect of the polymorphism [8]. Although
canalization of genetic effects needs to be considered when
interpreting MR findings, this problem is very difficult to investigate.
Finally, one could speculate that the observed association of the
subject’s iron-related genotype with PD risk might actually reflect an
intrauterine effect of iron due to a similar iron-related maternal
genotype. Some evidence suggests that maternal iron deficiency could
result in an altered iron status of the newborn, with possible negative
effects on the neurophysiologic development [67].
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Despite all the possible limitations discussed above, MR offers a
valuable approach to derive causal effect estimates whenever
randomized trials are very difficult to perform, as in the case of
iron and PD. A trial investigating the long-term effect of changes
in a subject’s iron status, obtained by some means, on the risk of
developing PD would require not only a very long follow-up but
also a huge sample size, given the low frequency of the disease and
the magnitude of the effect that might realistically be expected.
In our study, theMR analysis to combine the OR of the gene–PD
association with the effect of the gene–iron association was based on
a Wald-type estimator, which works under a ‘‘rare disease
assumption’’ that is appropriate in the case of PD. However, the
use of a Wald-type estimator for the MR analysis of binary
outcomes represents only an approximate method andmay produce
biased MR estimates [32]. Although such bias has been recently
shown to be small, typically within 10% of the MR estimate [68],
methods in this area are still under active development.
In summary, our MR study suggests a causal association
between increased serum iron levels and decreased risk of
developing PD, suggesting that disrupted iron metabolism may
be an important factor in the pathogenesis of PD. However,
further research is needed to elucidate the pathophysiological
mechanism of action underlying our findings. The effect of dietary
iron or drugs capable of altering the balance between serum iron
and iron storage compartments, might prove to be suitable to test
in experimental models. The development of such disease models
is therefore necessary before any public health or clinical
recommendation can be made for primary prevention in subjects
at high risk of developing PD.
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boxes indicate the genetic (additive) effects of individual studies, with
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boxes indicate the genetic (additive) effects of individual studies, with
the size of the box being inversely proportional to the variance and
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weighted fixed-effect meta-analysis, and its 95% confidence interval.
The full vertical line shows the value for no effect, as opposed to the
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Figure S3 Forest plot of the meta-analysis of the studies
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The boxes indicate the genetic (additive) effects of individual
studies, with the size of the box being inversely proportional to the
variance and horizontal lines indicating 95% confidence intervals.
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inverse-variance weighted fixed-effect meta-analysis, and its 95%
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effect, as opposed to the dashed line indicating the estimated
pooled effect.
(TIF)
Figure S4 Sensitivity analysis: Forest plot of the men-
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Editors’ Summary
Background. Parkinson disease is a degenerative disorder
of the central nervous system caused by the death of
dopamine-generating cells in the substania nigra, a region of
the midbrain. The earliest symptoms are usually movement-
related and include tremor, slow movements, and difficulty
walking, and later cognitive and behavioral problems may
arise, with dementia commonly occurring in the advanced
stages of the disease. Parkinson disease affects around ten
million people world-wide and incidence increases with age,
with men more affected than women. To date, the causes of
Parkinson disease remain unknown although a combination
of genetic and environmental factors is thought to play a
role. Identifying possible modifiable risks is an important
step in the possible prevention of Parkinson disease.
Why Was This Study Done? Previous studies have shown
a possible association between lower blood levels of iron in
people with Parkinson disease compared with controls,
although the quality of these studies makes this finding
difficult to interpret. So in this study, the researchers used a
mendelian randomization approach to investigate whether
there was any evidence of an effect of blood iron levels on
the risk of Parkinson disease and if so to further explore the
direction and scale of any link. Mendelian randomization is a
method of using measured variation in genes of known
function to examine the causal effect of a modifiable
exposure on disease in situations where it is inappropriate
to perform a randomized controlled trial.
What Did the Researchers Do and Find? The researchers
estimated the effect of blood iron levels on the risk of
Parkinson disease using three polymorphisms in two genes,
HFE and TMPRSS6. For each polymorphism, they performed a
meta-analysis combining the results of studies investigating
the genetic effect on iron levels, which included almost
22,000 people from Europe and Australia, and a meta-
analysis of studies investigating the genetic effect on the risk
of Parkinson disease, which included a total of 20,809 people
with Parkinson disease and 88,892 controls from Europe and
North America. They then performed three separate men-
delian randomization analyses to estimate the effect of iron
on Parkinson disease for the three polymorphisms. By
combining the three estimates, they obtained a statistically
significant odds ratio of 0.97 for Parkinson disease per 10 mg/
dl increase in iron, corresponding to a 3% reduction in the
risk of Parkinson disease for every 10 mg/dl increase in blood
iron. Since genotype influences on blood iron levels
represent differences that generally persist throughout adult
life, the combined mendelian randomization estimate
reflects an effect of iron over the course of a lifetime.
What Do These Findings Mean? These findings suggest
that increased iron levels in the blood are associated with a
3% reduction in the risk of Parkinson disease for every 10 mg/
dl increase in iron. This finding is important as it suggests
that increased blood iron levels may have a protective effect
against Parkinson disease, although the underlying mecha-
nism remains unclear. Furthermore, although mendelian
randomization is an increasingly used approach to address
the issue of classical confounding, there may be remaining
confounding factors specific of mendelian randomization
that may influence the interpretation of this study. Never-
theless, the results of this analysis have potentially important
implications for future research into the prevention of
Parkinson disease. Further studies on the underlying mech-
anisms are needed before any specific treatment recom-
mendations can be proposed.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001462.
N The National Institutes of Neurological Disorder and
Stroke, MedlinePlus, and NHS Choices have several pages
with comprehensive information on Parkinson disease
N Wikipedia gives an explanation of mendelian
randomization (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several
languages)
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